Category Archives: USTR 301 report

Please-all IPR policy pleases none

India’s new intellectual property rights (IPR) policy attempts to address concerns of developed countries regarding India’s patent regime, while also protecting public interest, especially that of generic drug producers. However, through this effort of a balancing act, India might have … Continue reading

Posted in IPR, IPR policy, Uncategorized, USTR 301 report | Leave a comment

US pressure on India – MSF’s note on Release of 2016 US Trade 301 Watch List Report

April 27, 2016 – The United States Trade Representative’s (USTR) 2016 “Special 301 Report” was released yesterday. Many countries – including India – are targeted and put on a ‘Priority Watch List’ for using legal tools to protect generic competition … Continue reading

Posted in Compulsory Licensing, Uncategorized, USTR 301 report | Leave a comment

US continues to keep India on intellectual property priority watch list

By Kritika Suneja, ET Bureau| April 27, 2016 NEW DELHI: India continues to figure in the US’ Priority Watch List that identifies trade barriers to US companies due to intellectual property laws of other countries.

Posted in IPR, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

On IP Protection, USTR Finds Fault With China, India … And Switzerland?

BY WILLIAM NEW, INTELLECTUAL PROPERTY WATCH| April 27, 2016 The Office of the United States Trade Representative (USTR) does not hesitate to add even its closest friends to its annual list of concerns about possible inadequate protection of US intellectual … Continue reading

Posted in IPR, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

An Unethical and Unwarranted Assurance

Source: Economic & Political Weekly| Vol. 51, Issue No. 12, 19 Mar, 2016 The Government of India gives “private assurances” to its friends in Big Pharma in the United States.  The compulsory licence is the definitive instrument in the amended Patents … Continue reading

Posted in Compulsory Licensing, Uncategorized, USTR 301 report | Leave a comment

Review Submission to USTR by US industry bodies raises alarm

U.S. India Business Council (USIBC) in a submission to U.S. Trade Representatives (USTR) for the 2016 Special 301 Review has clearly stated “the Government of India has privately reassured it would not use Compulsory Licenses (CL) for commercial purposes.”; indicating … Continue reading

Posted in Compulsory Licensing, Uncategorized, USTR 301 report | Leave a comment

U.S. industry body says India agreed to not issue ‘compulsory’ drug licences

By Zeba Siddiqui, Reuters|March 9, 2016 India has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western drugmakers, a U.S. business advocacy group said.

Posted in Compulsory Licensing, Special 301 report, Uncategorized, USTR 301 report | Leave a comment